10 citations
,
March 2023 in “Journal of Chemistry” This study identified ten novel compounds that may effectively target steroid 5 alpha-reductase 2 (5αR-2) for potential treatment of benign prostate hyperplasia, exhibiting comparable binding energies to existing drugs like finasteride and dutasteride.
13 citations
,
January 2015 in “Steroids” This study generated a pharmacophoric model for both isoforms of steroidal 5α-reductase using 6-azasteroids, providing a structural framework for designing new inhibitors.
May 2024 in “Scientific African” This research used computational methods to identify potential new treatments for benign prostatic hyperplasia, finding three compounds from Ghanaian plants with promising binding energy against 5alpha reductase 2 compared to existing drugs, yet further in vitro validation is necessary to confirm their efficacy.
20 citations
,
February 2002 in “Expert Opinion on Therapeutic Patents” This review discusses the potential uses of 5α-reductase inhibitors for conditions ranging from benign prostatic hyperplasia to skin disorders like acne and male pattern baldness, but it reports no new clinical results.
2 citations
,
July 2025 in “Discover Chemistry.” This study explored the optimization of phytochemicals from Alstonia boonei to develop potential 5-alpha reductase inhibitors for Benign Prostatic Hyperplasia, finding promising analogs with enhanced binding affinity and stability compared to Finasteride, warranting further experimental validation.